Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

State attorneys general and federal prosecutors alleged Gilead Sciences illegally bankrolled lavish events for prescribers.

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...